AstraZeneca: collaboration deal to increase COVID-19 testing
(CercleFinance.com) - French diagnostics firm Novacyt is collaborating with AstraZeneca, GSK and the University of Cambridge to increase testing for COVID-19, the company said on Wednesday.
Under the deal, a new testing facility will be set up by AstraZeneca and GSK at a University of Cambridge laboratory, which will be used for high throughput screening for COVID-19 testing.
The site will also explore the use of alternative chemical reagents for test kits in order to help overcome current supply shortages, Novacyt said.
As part of the collaboration, Novacyt will ensure the workflow process within the facility for COVID-19 testing, also providing its COVID-19 test to generate results, it said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Under the deal, a new testing facility will be set up by AstraZeneca and GSK at a University of Cambridge laboratory, which will be used for high throughput screening for COVID-19 testing.
The site will also explore the use of alternative chemical reagents for test kits in order to help overcome current supply shortages, Novacyt said.
As part of the collaboration, Novacyt will ensure the workflow process within the facility for COVID-19 testing, also providing its COVID-19 test to generate results, it said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.